Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder

TitreTranscutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder
Type de publicationArticle de revue
AuteurLeroux, Pierre-Adrien, Brassart, Elena, Lebdai, Souhil , Azzouzi, Abdel Rahmene , Bigot, Pierre , Carrouget, Julie
TypeArticle scientifique dans une revue à comité de lecture
DateSeptembre 2018
Titre de la revueWorld Journal of Urology
Mots-clésAdult, Aged, Aged, 80 and over, Cholinergic Antagonists, Drug resistance, Female, Follow-Up Studies, Humans, Male, Middle Aged, Prospective Studies, Tibial Nerve, Time Factors, Transcutaneous Electric Nerve Stimulation, Treatment Outcome, Urinary Bladder, Overactive
Résumé en anglais

PURPOSE: To evaluate long-term use, efficacy and tolerability of transcutaneous tibial nerve stimulation (TTNS) in the treatment of refractory overactive bladder (OAB).

METHODS: We performed a prospective observational study and included all patients treated in a single center for OAB persisting after first-line anticholinergic treatment, with ≥ 24 months follow-up. The protocol consisted of daily stimulation at home. The primary outcome was treatment persistence. Amelioration was defined as an improvement in urinary symptom profile (USP) score.

RESULTS: We assessed 84 consecutive patients. After a mean follow-up of 39.3 months and a mean treatment use of 8.3 months, almost two-thirds of patients (71.8%) had discontinued TTNS. Treatment continuation was > 12 months for 28 patients (33.3%) and > 18 months for 16 patients (19%). TTNS was successful following 3 months of treatment in 60 (71%) patients. Mean USP score stayed significantly lower than baseline until 12 months of treatment, but was not significant anymore after 18 months. Discontinuation therapy reasons were a lack of sufficient symptom relief for 59 (70%) patients, compliance difficulty for 5 (6%) patients and becoming asymptomatic for 6 (8%) patients. No serious adverse events occurred.

CONCLUSIONS: The present study confirms the utility of TTNS as a treatment option for patients with resistant OAB. In the long-term use, few patients continued with therapy, mostly because of a decreased effectiveness with time.

URL de la notice
Lien vers le document

Titre abrégéWorld J Urol
Identifiant (ID) PubMed29633085